SBFMNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFMW
Sunshine Biopharma Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.24+0.02 (+9.02%)
Close on Oct 19, 2026
- Market cap
- $330.14K
- P/E (TTM)
- –
- Dividend yield
- –
Sunshine Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Market Cap | $937.54K | $164.85M |
| Enterprise Value | -$12.81M | $87.06M |
| PS Ratio | 0.03 | 3.60 |
| PB Ratio | 0.03 | 2.03 |
| P/TBV Ratio | 0.04 | 2.31 |
Enterprise value
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| EV / Sales | -0.36 | 2.43 |
Income (trailing twelve months)
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Revenue | $35.35M | $57.94M |
| Gross Profit | $10.71M | $90.47M |
| Operating Income | -$5.89M | -$21.44M |
| Pretax Income | -$5.56M | -$14.45M |
| Net Income | -$5.83M | -$22.46M |
| EBITDA | -$5.54M | -$16.91M |
| EPS (Diluted) | -$2.00 | -$0.83 |
Margins
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Gross Margin | 30.3% | 52.3% |
| Operating Margin | -16.6% | -44.5% |
| Pretax Margin | -15.7% | -13.0% |
| Profit Margin | -16.5% | -39.2% |
| EBITDA Margin | -15.7% | -31.3% |
| FCF Margin | -15.2% | -8.85% |
Returns
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -21.9% | -53.1% |
| Return on Assets (ROA) | -17.8% | -41.0% |
| Return on Invested Capital (ROIC) | -31.9% | -32.0% |
| Return on Capital Employed (ROCE) | -21.0% | -37.8% |
Growth
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -2.74% | 6.01% |
| Revenue Growth (3Y CAGR) | 102.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 247.7% | 6.42% |
Balance sheet
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $13.75M | $62.42M |
| Net Cash (Debt) | $13.75M | $15.68M |
| Net Cash Per Share | $3.55 | $0.66 |
| Equity (Book Value) | $27.54M | $48.79M |
| Book Value Per Share | $7.10 | $1.36 |
| Tangible Book Value | $25.70M | $23.06M |
| Working Capital | $25.05M | $75.77M |
Financial position
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Current Ratio | 5.46 | 3.30 |
| Quick Ratio | 3.16 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$5.35M | -$12.35M |
| Capital Expenditures | -$19.15K | -$1.06M |
| Free Cash Flow | -$5.37M | -$20.28M |
| FCF Per Share | -$1.39 | -$0.42 |
Efficiency
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Asset Turnover | 1.08 | 0.38 |
| Inventory Turnover | 1.96 | 2.67 |
| Revenue Per Employee | $706.94K | $398.96K |
| Profits Per Employee | -$116.65K | -$703.34K |
| Employee Count | 50 | 74 |
Dividends and yields
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Earnings Yield | -622.1% | -22.7% |
| FCF Yield | -573.0% | -9.07% |
Shares
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 3,877,340 | 58,179,650 |
| Shares Change (YoY) | 96.8% | 11.1% |
| Shares Change (QoQ) | -51.3% | 0.54% |
| Float | 3,809,040 | 49,173,100 |
| Shares Held by Insiders | 1.76% | 11.6% |
| Shares Held by Institutions | 2.08% | 59.4% |
Taxes
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Income Tax | $270.94K | $91.50K |
Scores
| Measure | Sunshine Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | -1.78 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Sunshine Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.